



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/896,888	06/29/2001	Tom A. Grigliatti	4810-59380	3346
7590 11/01/2004		EXAMINER		
KLARQUIST SPARKMAN CAMPBELL LEIGH & WHINSTON, LLP			VOGEL, NANCY S	

One World Trade Center Suite 1600 121 S.W. Salmon Street Portland, OR 97204

ART UNIT PAPER NUMBER 1636

DATE MAILED: 11/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/896,888	GRIGLIATTI ET AL.				
Advisory Action	Examiner	Art Unit				
	Nancy T. Vogel	1636				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 22 September 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires 3_months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) \times they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) ☐ they raise the issue of new matter (see Note below);						
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) M they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☑ The a) ☑ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: See	r reconsideration has been consecutive Continuation Sheet.	sidered but does NOT place the				
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w	t(s) a)□ will not be entered or bould be rejected is provided bel	o)□ will be entered and an ow or appended.				
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to: 2 and 3.						
Claim(s) rejected: 1, 4-17, 23 and 27-29.						
Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Stateme	ent(s)( PTO-1449) Paper No(s).					
10. Other:	,					

Continuation Sheet (PTOL-303) 009/896,888

Continuation of 2. NOTE: Proposed new claims 30-33 as well as the amendment to claim 8 raise new issues which do not materially reduce or simplify the issues for appeal, and which would require further consideration and search. For instance, new claim 30 recites that the prokaryotic promoter sequence "is a cryptic promoter within said insect promoter", which raises new issues that would require further search and consideration, and which have not previously been subject to a complete search and consideration.

Continuation of 5. does NOT place the application in condition for allowance because: while applicant argues that other selection markers need not be exemplified by the specification in order to satisfy the written description, it is maintained that the specification must provide a written description of the claimed subject matter with reasonable clarity to show that they were in possession of the invention as claimed at the time of filing. Page 67, lines 20-21, pointed to by applicants to support their assertion that selection systems were described, merely states that "[i]n some embodiemnets, the vectors of the invention may be adapted for use with a variety of antibiotic selection schemes", which fails to allow the skilled artisan to envision the detailed chemical structure of the encompassed genus of antibiotic selections. The declaration of Dr. Grigliatti, showing other antibiotic selection schemes, is not found convincing, since the information disclosed therein is not part of the specification and therefore does not remedy the lack of written description therein.

TERRY MCKELVEY
PRIMARY EXAMINER